(R)-N-Desacryloyl N-3-Propionyl Ibrutinib

(R)-N-Desacryloyl N-3-Propionyl Ibrutinib is a highly potent and selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). BTK is a key enzyme involved in the B-cell receptor signaling pathway, which is important for the survival and proliferation of B-cells. This signaling pathway is also implicated in the pathogenesis of B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). (R)-N-Desacryloyl N-3-Propionyl Ibrutinib has been shown to be effective in the treatment of these B-cell malignancies, both as a single agent and in combination with other therapies. It works by irreversibly binding to BTK, thereby inhibiting its activity and preventing the downstream signaling cascade. This leads to a reduction in B-cell proliferation and survival, as well as inhibition of cell migration and adherence to the microenvironment. (R)-N-Desacryloyl N-3-Propionyl Ibrutinib has a chemical formula of C26H25N5O3 and a molecular weight of 463.51 g/mol. It has a melting point of 200-205°C and is soluble in DMSO and ethanol. The compound is administered orally and is rapidly absorbed, with a half-life of approximately 4-6 hours. It is metabolized in the liver and excreted through the feces and urine. In conclusion, (R)-N-Desacryloyl N-3-Propionyl Ibrutinib is a promising therapeutic agent for the treatment of B-cell malignancies. Its potent and selective inhibition of BTK makes it a valuable addition to the armamentarium against these diseases.